Myxedema coma, a rare life-threatening complication of hypothyroidism, is a loss of brain function. This extreme manifestation of hypothyroidism is an infrequent but potentially fatal condition. Women are four times more prone to suffer from hypothyroidism compared to men and correspondingly 80 percent incidences of myxedema coma occur in females. If seasonality is to be considered above 90% cases happen in winters.
This seasonal prevalence could be apparently because of inability to sense temperature and lower body heat production in the elderly, secondary to hypothyroidism. Major symptoms of myxedema coma include abnormal low body temperature (sometimes as low as 80 degrees F), severe mental conditions (like hallucinations, seizers, disorientation), edema with swollen eyes, hair loss, difficulty in breathing among many more. The best of treating myxedema coma is preventing it in the first place. The factors which could trigger myxedema coma are certain types of drugs, heart stroke, gastrointestinal bleeding, trauma, infections, and not taking prescribed thyroid medications.
The ongoing COVID-19 pandemic has taken all the focus of researchers and industry players which has resulted in pushing back of already less researched niche domains like myxedema coma. Additionally, the financial demands of rare diseases like myxedema coma are unmet due to persion of funds towards more pressing needs experienced due to COVID-19.
Request For Sample Copy: https://www.persistencemarketresearch.com/samples/31863
Myxedema Coma Market: Drivers and Restraints
In case of myxedema coma, the family physicians are in an important position to prevent the condition by maintaining a high level of suspicion for hypothyroidism during the regular follow up visits. Hence growing awareness among people to pay regular visit to doctors will be a key driver for the growth of myxedema coma market. Another reason which could drive the global myxedema coma treatment market is high mortality rate in the patients which is reported up to 60%. The pharmaceutical moguls would like to bring down this rate substantially.
Get in Touch with Industry Expert @ https://www.persistencemarketresearch.com/ask-an-expert/31863
Myxedema Coma Market: Overview
With the estimated cases at 1.08 cases per million and total cases at approximately 7000 cases per year worldwide per year, the overall myxedema coma treatment market is expected to record a steady growth. By drug class, the natural origin segment in the global myxedema coma market is expected to witness a robust growth based on patient preferences.
By route of administration, oral segment in the global myxedema coma market is estimated to grow faster than the injectable segment owing to patient convenience. By distribution channel, retail pharmacies in the global myxedema coma market are estimated to register a sound growth.
Request for Pre Book @ https://www.persistencemarketresearch.com/checkout/31863
About Us :-
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Persistence Market Research
Address – 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – email@example.com
Website – https://www.persistencemarketresearch.com